Sana Biotechnology receives FDA IND clearance for SC291 allogeneic CAR T therapy in B-cell malignancies

Sana Biotechnology, Inc.

FDA cleared IND for SC291, a CD19-targeted allogeneic CAR T therapy using Sana's hypoimmune platform, in patients with B-cell lymphomas or leukemias.
Goal to report initial SC291 clinical data in 2023; second IND for SC262 (CD22-targeted) expected this year.
Hypoimmune platform disrupts MHC class I/II expression and overexpresses CD47 to evade immune rejection.
Preclinical data shown across models; platform also being developed for pancreatic islet cell therapy in type 1 diabetes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.